Table 1. Baseline characteristics of nondiabetic stroke patients.
| Demographic characteristics | Patients |
|---|---|
| n | 266 |
| Male sex (%) | 145 (54.5) |
| Age (years), median (IQR) | 59 (54–65) |
| BMI (kg.m−2), median (IQR) | 26.5 (24.9–28.6) |
| Stroke severity, median NIHSS score (IQR) | 7 (3–14) |
| Vascular risk factors number (%) | |
| Hypertension | 176 (75.9) |
| Atrial fibrillation | 45 (19.4) |
| Coronary heart disease | 65 (28.0) |
| Family history for stroke | 51 (22.0) |
| Current cigarette smoking | 55 (23.7) |
| Pre-stroke treatment, number (%) | |
| Anti-hypertensive treatment | 142 (53.4) |
| Statins | 62 (23.3) |
| Anticoagulants | 41 (15.4) |
| Acute treatment, number (%) | 59 (22.2) |
| TPA-T number (%) | 41 (15.4) |
| Stroke etiology number (%) | |
| Small-vessel occlusive | 51(19.2) |
| Large-vessel occlusive | 58 (21.8) |
| Cardioembolic | 102 (38.3) |
| Other | 34 (12.8) |
| Unknown | 21 (7.9) |
| Laboratory findings (IQR) | |
| Total cholesterol (mmol.l−1) | 4.3 (3.4–5.3) |
| High-density lipoproteins (mmol.l−1) | 1.3 (1.0–1.8) |
| FBG (mmol.l−1) | 5.4 (5.1–5.8) |
| Hs-CRP (mg.dl−1) | 0.64 (0.35–1.06) |
| tHCY (mmol.l−1) | 19 (15–23) |
| 25(OH) D (mmol.l−1) | 18 (13–24) |
Abbreviations: Hs-CRP, high CRP tHCY, total homocysteine; TPA-T, Tissue plasminogen activator treatment